Skip to main content

Table 1 Chronic symptoms in ENVISION trial participants at baseline

From: Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study

Characteristic

Placebo (n = 46)

Givosiran (n = 48)

Total (N = 94)

Prior chronic symptoms, n (%)

26 (57)

23 (48)

49 (52)

Prior chronic opioid use, n (%)

13 (28)

14 (29)

27 (29)

Nausea symptoms (medical history), n (%)

10 (22)

7 (15)

17 (18)

Fatigue (medical history), n (%)

4 (9)

1 (2)

5 (5)

Daily worst nausea score, weekly mean (SD)

1.9 (1.8)

1.6 (1.7)

1.7 (1.8)

Daily worst fatigue score, weekly mean (SD)

4.7 (2.3)

4.1 (2.6)

4.4 (2.5)

Daily worst pain score, weekly mean (SD)

3.7 (2.2)

3.0 (2.3)

3.3 (2.3)

Bodily pain domain score (SF-12), mean (SD)

34.4 (9.0)

37.6 (9.9)

36.0 (9.6)

  1. SF-12 12-Item Short-Form Health Survey, version 2